Cash and cash equivalents totaled $10 million as of March 31, 2025, compared to $11.6 million as of December 31, 2024. Subsequent to closing of the public offering on May 8 2025, the Company’s cash balance was $14.1 million.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Completes $7.5 Million Public Offering
- Theriva Biologics downgraded to Hold from Buy at Maxim
- Theriva Biologics prices 6.8M shares at $1.10 in public offering
- Theriva Biologics announces primary endpoints for efficacy met in VIRAGE study
- Theriva Biologics Announces Positive VIRAGE Phase 2b Results